WHAT IS CLAIMED IS:

1. A compound for use in treating gout in a patient on concomitant thiazide diuretics, wherein the patient is not adequately responding to a non-lesinurad urate lowering therapy, wherein the compound is lesinurad.

2. The compound for use of claim **1**, wherein a dose of lesinurad is 200 mg.

3. The compound for use of claim **1**, wherein a dose of lesinurad is 400 mg.

4. The compound for use of claim **1**, wherein the non-lesinurad urate lowering therapy is allopurinol.

5. A compound for use in reducing the incidences of or likelihood of or reversing hyperuricemia or gout in a patient receiving thiazide treatment, wherein the compound is an OAT4 inhibitor.

6. The compound for use of claim 5, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

7. The compound for use of claim 5, wherein the thiazide treatment is treatment with hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, chlorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.

8. A compound for use in reducing or reversing hyperuricemia or gout in a patient receiving hydrochlorothiazide, wherein the compound is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

9. A compound for use in reducing serum uric acid levels in a patient suffering from hypertension, wherein the compound is an OAT-4 inhibitor,

   wherein the patient is receiving a thiazide diuretic, and

   wherein administration of the thiazide diuretic results in elevated serum uric acid levels.

10. The compound for use of claim 9, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

11. A composition comprising:

    (i) a thiazide diuretic;

    (ii) an OAT-4 inhibitor; and

    (iii) a pharmaceutically acceptable excipient or carrier.

12. A composition comprising:

(i) a thiazide diuretic;

(ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient or carrier.

13. A composition comprising:

(i) hydrochlorothiazide;

(ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient or carrier.

WHAT IS CLAIMED IS:

1. A method for treating hypertension in a subject in need thereof, wherein said treatment does not result in an increase in serum uric acid levels, comprising administering to the subject:

   (i) a thiazide diuretic; and

   (ii) an OAT4 inhibitor.

2. The method of claim **1**, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

3. The method of claim **1**, wherein the thiazide diuretic is selected from hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, clorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.

4. The method of claim **1**, further comprising administering a URAT1 inhibitor.

5. The method of claim **4**, wherein the OAT4 inhibitor and the URAT1 inhibitor are the same drug.

6. The method of claim **5**, wherein the drug is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

7. A method for treating hypertension in a subject in need thereof, wherein said treatment does not result in an increase in serum uric acid levels, comprising administering to the subject:

   (i) hydrochlorothiazide; and

   (ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

8. A method for reducing the incidences of or likelihood of or reversing the diagnosis of hyperuricemia or gout in a patient receiving thiazide treatment, comprising administering an OAT4 inhibitor to the patient.

9. The method of claim **8**, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

10. The method of claim **8**, wherein the thiazide treatment is treatment with hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, clorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide.

11. A method for reducing or reversing the diagnosis of hyperuricemia or gout in a patient receiving hydrochlorothiazide, comprising administering 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

12. A method for reducing serum uric acid levels in a patient suffering from hypertension, comprising administering to the subject an effective amount of an OAT-4 inhibitor,

wherein the patient is receiving a thiazide diuretic, and

wherein administration of the thiazide diuretic results in elevated serum uric acid levels.

13. The method of claim **12**, wherein the OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof.

14. A composition comprising:

(i) a thiazide diuretic;
(ii) an OAT-4 inhibitor; and
(iii) a pharmaceutically acceptable excipient or carrier.

15. A composition comprising:

(i) hydrochlorothiazide;

(ii) 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof; and

(iii) a pharmaceutically acceptable excipient or carrier.